Showing results (1351-1360 of 1,365) with videos related to

Sort By:
Pageof 137
Nature|October 1, 2024
Silicon heterojunction back-contact solar cells by laser patterningHua Wu, Feng Ye, Miao Yang, et al.
Gut|July 25, 2025
Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologiesJinjin Luo, Meiqian Hu, Tingting Feng, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2020
Peritoneal Dialysis Use and Practice Patterns: An International Survey StudyYeoungjee Cho, Aminu K Bello, Adeera Levin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2020
Hemodialysis Use and Practice Patterns: An International Survey StudyHtay Htay, Aminu K Bello, Adeera Levin, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
BMJ (Clinical Research Ed.)|November 2, 2019
Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional surveyAminu K Bello, Adeera Levin, Meaghan Lunney, et al.
The European Respiratory Journal|March 29, 2020
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysisWei-Jie Guan, Wen-Hua Liang, Yi Zhao, et al.
The European Respiratory Journal|April 10, 2020
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of ChinaWen-Hua Liang, Wei-Jie Guan, Cai-Chen Li, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 137